Nitroglycerin


Curated chemical-phenotype interactions from CTD
GO IDGO nameInteraction typeReference
GO:0002027 Regulation of heart rate Increases phenotype PMID:100259; PMID:1913759; PMID:19660000; PMID:21609410; PMID:6430077; PMID:6775290; PMID:6793373; PMID:9527094; PMID:102330; PMID:409604; PMID:8430630
GO:0002523 Leukocyte migration involved in inflammatory response Increases phenotype PMID:36305384
GO:0004069 L-aspartate:2-oxoglutarate aminotransferase activity Increases phenotype PMID:36305384
GO:0004364 Glutathione transferase activity Increases phenotype PMID:27758841
GO:0004457 Lactate dehydrogenase activity Increases phenotype PMID:27758841
GO:0006915 Apoptotic process Affects phenotype PMID:16622039; PMID:17322376
GO:0006979 Response to oxidative stress Increases phenotype PMID:19246430
GO:0008217 Regulation of blood pressure Increases phenotype PMID:100259; PMID:16235461; PMID:6778626; PMID:803231; PMID:8430630; PMID:10753287; PMID:15198873; PMID:1836097; PMID:18843604; PMID:1913759; PMID:19336651; PMID:21609410; PMID:2571590; PMID:3085502; PMID:3134810; PMID:3304958; PMID:417150; PMID:6804108; PMID:819021; PMID:9527094; PMID:9829161; PMID:16391172; PMID:17973874; PMID:6430077; PMID:9366762; PMID:17973874; PMID:1913759; PMID:3134810; PMID:2114438; PMID:2571590; PMID:2900259; PMID:409604; PMID:6430077
GO:0019722 Calcium-mediated signaling Affects phenotype PMID:10389777
GO:0030154 Cell differentiation Decreases phenotype PMID:16622039
GO:0034440 Lipid oxidation Increases phenotype PMID:36305384
GO:0042119 Neutrophil activation Affects phenotype PMID:10884648; PMID:8869312
GO:0042310 Vasoconstriction Affects phenotype PMID:10389777; PMID:14688690; PMID:15519194; PMID:1906905; PMID:2022013; PMID:23194305; PMID:2973376; PMID:3110237; PMID:3131874; PMID:7810184; PMID:8737102
GO:0042311 Vasodilation Affects phenotype PMID:10440166; PMID:15769980; PMID:8579031; PMID:10979640; PMID:11153725; PMID:11153725; PMID:17251671; PMID:7642851; PMID:11230718; PMID:11231994; PMID:11231994; PMID:15505499; PMID:19247267; PMID:11557915; PMID:11733111; PMID:11867031; PMID:8430630; PMID:15769980; PMID:17351371; PMID:19246430; PMID:19247267; PMID:20490904; PMID:3304958; PMID:6804108; PMID:8837571; PMID:9990214; PMID:25576686; PMID:28342890; PMID:7642851; PMID:7729008; PMID:9024144
GO:0042428 Serotonin metabolic process Affects phenotype PMID:36924863
GO:0045907 Positive regulation of vasoconstriction Increases phenotype PMID:30033381
GO:0046209 Nitric oxide metabolic process Affects phenotype PMID:32147481
GO:0046466 Membrane lipid catabolic process Affects phenotype PMID:10884648; PMID:17322376; PMID:27758841; PMID:9874048
GO:0050965 Detection of temperature stimulus involved in sensory perception of pain Increases phenotype PMID:32147481
GO:0060087 Relaxation of vascular associated smooth muscle Decreases phenotype PMID:24296279
GO:0061368 Behavioral response to formalin induced pain Increases phenotype PMID:32147481
GO:0071897 Dna biosynthetic process Increases phenotype PMID:36305384
GO:1903283 Negative regulation of glutathione peroxidase activity Increases phenotype PMID:27758841
DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.